Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic options in IgA nephropathy.

A R Clarkson1, A J Woodroffe, I A Aarons

  • 1Renal Unit, Royal Adelaide Hospital, Australia.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|November 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robotic retroperitoneal lymph-node dissection for testicular cancer: initial experience.

Journal of robotic surgery·2025
Same author

Controlling a new plasma regime.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2024
Same author

On the Utility of Trisnitrate of Bismuth in the Diarrhea Accompanying Phthisis.

Western journal of medicine and surgery·2024
Same author

H. pylori predictors and outcomes among adults undergoing upper endoscopy at a Jamaican teaching hospital: A cross-sectional study.

Helicobacter·2023
Same author

Chronic pain through COVID.

Frontiers in pain research (Lausanne, Switzerland)·2022
Same author

Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.

European review for medical and pharmacological sciences·2021

IgA nephropathy (IgAN) is a common kidney disease. Current treatments lack clear benefits, highlighting the need for better understanding of its causes and exploring new therapeutic strategies.

Area of Science:

  • Nephrology
  • Immunology
  • Pathogenesis of Kidney Disease

Background:

  • IgA nephropathy (IgAN) is a prevalent glomerular disease.
  • It progresses to end-stage renal disease in 20-30% of patients.
  • Understanding IgAN pathogenesis is crucial for effective treatment.

Purpose of the Study:

  • To review current therapeutic approaches for IgA nephropathy.
  • To identify gaps in understanding IgAN pathogenetic mechanisms.
  • To suggest future research directions for IgAN treatment.

Main Methods:

  • Review of existing literature on IgA nephropathy treatments.
  • Analysis of uncontrolled trials and their outcomes.
  • Identification of unmet needs in IgAN therapy.

Related Experiment Videos

Main Results:

  • Current therapies targeting immune complexes, cellular immunity, or antigen removal show no clear benefits.
  • Existing treatment strategies are often based on uncontrolled trials.
  • The pathogenetic mechanisms underlying IgAN remain largely unknown.

Conclusions:

  • There is a significant need for improved understanding of IgA nephropathy pathogenesis.
  • Novel therapeutic strategies are required to alter glomerular hemodynamics and prevent harmful mediators.
  • Further research into IgAN is essential for developing effective treatments and improving patient outcomes.